FDA Inspection 1202885 — Novartis Singapore Pharmaceutical Manufacturing Pte.
The FDA completed an inspection of Novartis Singapore Pharmaceutical Manufacturing Pte. on March 3, 2023 in Singapore. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 3, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Singapore (Singapore)